Tocqueville Asset Management L.P. Invests $38.54 Million in Boston Scientific Corporation $BSX

Tocqueville Asset Management L.P. purchased a new stake in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 902,984 shares of the medical equipment provider’s stock, valued at approximately $38,539,000.

A number of other institutional investors have also recently modified their holdings of the business. Brighton Jones LLC raised its position in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares in the last quarter. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter worth $26,000. Main Street Financial Solutions LLC boosted its position in shares of Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after purchasing an additional 1,971 shares in the last quarter. Ieq Capital LLC grew its stake in shares of Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after purchasing an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC grew its stake in shares of Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after purchasing an additional 2,556 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Up 3.1%

Shares of BSX opened at $52.02 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The stock has a market cap of $75.39 billion, a price-to-earnings ratio of 21.06, a price-to-earnings-growth ratio of 1.10 and a beta of 0.56. The firm has a 50 day simple moving average of $46.22 and a 200-day simple moving average of $58.22.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its board has authorized a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

BSX has been the subject of several recent analyst reports. Zacks Research cut shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Oppenheimer lowered their target price on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a research report on Monday, July 27th. Barclays reduced their price target on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research report on Thursday, May 28th. Leerink Partners set a $60.00 price target on Boston Scientific in a research note on Thursday, July 30th. Finally, Robert W. Baird set a $56.00 price target on Boston Scientific in a report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Insider Activity

In related news, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 194,522 shares of company stock worth $9,385,210 over the last three months. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.